Brief: Tcr Therapeutics Presents Preclinical Data On Functional Activity Of Gavo-Cel
TCR2 Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Heartbeam, Aura Biosciences, U.S. banks
U.S. STOCKS ON THE MOVE-Airlines, Thor Industries, TCR2 Therapeutics
TCR2 Therapeutics up on promising data from cancer therapy
Brief: TCR2 Therapeutics Announces Positive Topline Results From Phase 1 Portion Of Gavo-Cel Phase 1/2 Clinical Trial For Mesothelin-Expressing Solid Tumors
Brief: Tcr² Therapeutics To Announce Complete Phase 1 Portion Of The Gavo-Cel Phase 1/2 Clinical Trial For Mesothelin-Expressing Solid Tumors
Brief: Tcr² Therapeutics reports Q2 results
Brief: Tcr² Therapeutics Appoints Industry And Finance Veteran Eric Sullivan As Chief Financial Officer
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: TCR Therapeutics Reports First Quarter 2022 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Adobe, Aligos Therapeutics
U.S. RESEARCH ROUNDUP- Adobe, Aligos Therapeutics
Brief: TCR2 Therapeutics Reports Fourth Quarter 2021 Financial Results
TCR2 Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview
Brief: TCR² Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies
Brief: TCR2 Therapeutics CFO Somaiya Informs Co Of Intent To Resign